486 related articles for article (PubMed ID: 15792788)
1. Subconjunctivally administered celecoxib-PLGA microparticles sustain retinal drug levels and alleviate diabetes-induced oxidative stress in a rat model.
Ayalasomayajula SP; Kompella UB
Eur J Pharmacol; 2005 Mar; 511(2-3):191-8. PubMed ID: 15792788
[TBL] [Abstract][Full Text] [Related]
2. Single periocular injection of celecoxib-PLGA microparticles inhibits diabetes-induced elevations in retinal PGE2, VEGF, and vascular leakage.
Amrite AC; Ayalasomayajula SP; Cheruvu NP; Kompella UB
Invest Ophthalmol Vis Sci; 2006 Mar; 47(3):1149-60. PubMed ID: 16505053
[TBL] [Abstract][Full Text] [Related]
3. Retinal delivery of celecoxib is several-fold higher following subconjunctival administration compared to systemic administration.
Ayalasomayajula SP; Kompella UB
Pharm Res; 2004 Oct; 21(10):1797-804. PubMed ID: 15553225
[TBL] [Abstract][Full Text] [Related]
4. Celecoxib, a selective cyclooxygenase-2 inhibitor, inhibits retinal vascular endothelial growth factor expression and vascular leakage in a streptozotocin-induced diabetic rat model.
Ayalasomayajula SP; Kompella UB
Eur J Pharmacol; 2003 Jan; 458(3):283-9. PubMed ID: 12504784
[TBL] [Abstract][Full Text] [Related]
5. Subconjunctival nano- and microparticles sustain retinal delivery of budesonide, a corticosteroid capable of inhibiting VEGF expression.
Kompella UB; Bandi N; Ayalasomayajula SP
Invest Ophthalmol Vis Sci; 2003 Mar; 44(3):1192-201. PubMed ID: 12601049
[TBL] [Abstract][Full Text] [Related]
6. Effect of eye pigmentation on transscleral drug delivery.
Cheruvu NP; Amrite AC; Kompella UB
Invest Ophthalmol Vis Sci; 2008 Jan; 49(1):333-41. PubMed ID: 18172110
[TBL] [Abstract][Full Text] [Related]
7. Supercritical fluid technology based large porous celecoxib-PLGA microparticles do not induce pulmonary fibrosis and sustain drug delivery and efficacy for several weeks following a single dose.
Dhanda DS; Tyagi P; Mirvish SS; Kompella UB
J Control Release; 2013 Jun; 168(3):239-50. PubMed ID: 23562638
[TBL] [Abstract][Full Text] [Related]
8. Intratracheal budesonide-poly(lactide-co-glycolide) microparticles reduce oxidative stress, VEGF expression, and vascular leakage in a benzo(a)pyrene-fed mouse model.
Bandi N; Ayalasomayajula SP; Dhanda DS; Iwakawa J; Cheng PW; Kompella UB
J Pharm Pharmacol; 2005 Jul; 57(7):851-60. PubMed ID: 15969944
[TBL] [Abstract][Full Text] [Related]
9. Preparation of polylactide-co-glycolide nanoparticles incorporating celecoxib and their antitumor activity against brain tumor cells.
Kim TH; Jeong YI; Jin SG; Pei J; Jung TY; Moon KS; Kim IY; Kang SS; Jung S
Int J Nanomedicine; 2011; 6():2621-31. PubMed ID: 22114493
[TBL] [Abstract][Full Text] [Related]
10. Preparation of ONO-1301-loaded poly(lactide-co-glycolide) microspheres and their effect on nerve conduction velocity.
Hazekawa M; Sakai Y; Yoshida M; Haraguchi T; Morisaki T; Uchida T
J Pharm Pharmacol; 2011 Mar; 63(3):362-8. PubMed ID: 21749383
[TBL] [Abstract][Full Text] [Related]
11. Controlled delivery of ganciclovir to the retina with drug-loaded Poly(d,L-lactide-co-glycolide) (PLGA) microspheres dispersed in PLGA-PEG-PLGA Gel: a novel intravitreal delivery system for the treatment of cytomegalovirus retinitis.
Duvvuri S; Janoria KG; Pal D; Mitra AK
J Ocul Pharmacol Ther; 2007 Jun; 23(3):264-74. PubMed ID: 17593010
[TBL] [Abstract][Full Text] [Related]
12. Enhanced encapsulation and bioavailability of breviscapine in PLGA microparticles by nanocrystal and water-soluble polymer template techniques.
Wang H; Zhang G; Ma X; Liu Y; Feng J; Park K; Wang W
Eur J Pharm Biopharm; 2017 Jun; 115():177-185. PubMed ID: 28263795
[TBL] [Abstract][Full Text] [Related]
13. Biodegradable PLGA microspheres as a sustained release system for a new luteinizing hormone-releasing hormone (LHRH) antagonist.
Du L; Cheng J; Chi Q; Qie J; Liu Y; Mei X
Chem Pharm Bull (Tokyo); 2006 Sep; 54(9):1259-65. PubMed ID: 16946531
[TBL] [Abstract][Full Text] [Related]
14. Effect of diabetes on transscleral delivery of celecoxib.
Cheruvu NP; Amrite AC; Kompella UB
Pharm Res; 2009 Feb; 26(2):404-14. PubMed ID: 18987961
[TBL] [Abstract][Full Text] [Related]
15. Preparation and in vitro/in vivo evaluation of insulin-loaded poly(acryloyl-hydroxyethyl starch)-PLGA composite microspheres.
Jiang G; Qiu W; DeLuca PP
Pharm Res; 2003 Mar; 20(3):452-9. PubMed ID: 12669968
[TBL] [Abstract][Full Text] [Related]
16. Celecoxib-loaded poly(D,L-lactide-co-glycolide) nanoparticles prepared using a novel and controllable combination of diffusion and emulsification steps as part of the salting-out procedure.
McCarron PA; Donnelly RF; Marouf W
J Microencapsul; 2006 Aug; 23(5):480-98. PubMed ID: 16980271
[TBL] [Abstract][Full Text] [Related]
17. Controlled delivery of tauroursodeoxycholic acid from biodegradable microspheres slows retinal degeneration and vision loss in P23H rats.
Fernández-Sánchez L; Bravo-Osuna I; Lax P; Arranz-Romera A; Maneu V; Esteban-Pérez S; Pinilla I; Puebla-González MDM; Herrero-Vanrell R; Cuenca N
PLoS One; 2017; 12(5):e0177998. PubMed ID: 28542454
[TBL] [Abstract][Full Text] [Related]
18. Critical solvent properties affecting the particle formation process and characteristics of celecoxib-loaded plga microparticles via spray-drying.
Wan F; Bohr A; Maltesen MJ; Bjerregaard S; Foged C; Rantanen J; Yang M
Pharm Res; 2013 Apr; 30(4):1065-76. PubMed ID: 23263784
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of cyclooxygenase-2, but not cyclooxygenase-1, reduces prostaglandin E2 secretion from diabetic rat retinas.
Ayalasomayajula SP; Amrite AC; Kompella UB
Eur J Pharmacol; 2004 Sep; 498(1-3):275-8. PubMed ID: 15364005
[TBL] [Abstract][Full Text] [Related]
20. IKK2 inhibition using TPCA-1-loaded PLGA microparticles attenuates laser-induced choroidal neovascularization and macrophage recruitment.
Gaddipati S; Lu Q; Kasetti RB; Miller MC; Lu Q; Trent JO; Kaplan HJ; Li Q
PLoS One; 2015; 10(3):e0121185. PubMed ID: 25803615
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
